- Home
- HWBK vs TNXP Comparison
HWBK vs TNXP Comparison
Compare HWBK & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWBK
- TNXP
- Stock Information
- Founded
- HWBK 1865
- TNXP 2007
- Country
- HWBK United States
- TNXP United States
- Employees
- HWBK N/A
- TNXP N/A
- Industry
- HWBK Major Banks
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- HWBK Finance
- TNXP Health Care
- Exchange
- HWBK Nasdaq
- TNXP Nasdaq
- Market Cap
- HWBK 218.6M
- TNXP 213.7M
- IPO Year
- HWBK N/A
- TNXP N/A
- Fundamental
- Price
- HWBK $31.59
- TNXP $15.95
- Analyst Decision
- HWBK
- TNXP Buy
- Analyst Count
- HWBK 0
- TNXP 1
- Target Price
- HWBK N/A
- TNXP $70.00
- AVG Volume (30 Days)
- HWBK 11.1K
- TNXP 634.7K
- Earning Date
- HWBK 10-29-2025
- TNXP 11-10-2025
- Dividend Yield
- HWBK 2.53%
- TNXP N/A
- EPS Growth
- HWBK 259.86
- TNXP N/A
- EPS
- HWBK 3.19
- TNXP N/A
- Revenue
- HWBK $77,904,000.00
- TNXP $10,299,000.00
- Revenue This Year
- HWBK N/A
- TNXP $14.79
- Revenue Next Year
- HWBK N/A
- TNXP $933.49
- P/E Ratio
- HWBK $9.97
- TNXP N/A
- Revenue Growth
- HWBK 45.83
- TNXP N/A
- 52 Week Low
- HWBK $25.21
- TNXP $6.76
- 52 Week High
- HWBK $35.95
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- HWBK 63.69
- TNXP 30.30
- Support Level
- HWBK $30.83
- TNXP $16.10
- Resistance Level
- HWBK $31.96
- TNXP $18.34
- Average True Range (ATR)
- HWBK 0.60
- TNXP 1.08
- MACD
- HWBK 0.19
- TNXP 0.21
- Stochastic Oscillator
- HWBK 96.37
- TNXP 7.82
About HWBK Hawthorn Bancshares Inc.
Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.